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Abstract
Background: Governments in both developed and developing countries have adopted generic drug substitution policies
to decrease pharmaceutical expenditures and improve access to medicine. In August 2015, the Ministry of Public Health
(MOPH) in Lebanon introduced generic drug substitution and a unified medical prescription form as policy instruments to
promote generic drug use. The objective of this exploratory study was to examine the attitudes of community pharmacists
and the reported practices in relation to the implementation of the new generic drug substitution policy.
Methods: We used a cross-sectional mixed methods approach composed of self-administered questionnaires and semi-
structured interviews. The study population consisted of community pharmacists in Lebanon. We randomly approached
one pharmacy personnel from each selected community pharmacy. We conducted descriptive analyses to assess
responses to questionnaire and regression analyses to understand associations between responses and respondent
demographics. We analyzed qualitative data thematically.
Results: Out of 204 invited community pharmacies, 153 pharmacies participated (75% response rate). The majority of
respondents (64%) were in favor of generic drug substitution; however, less than half (40%) indicated they have substituted
brand drugs for generic equivalents. Moreover, 57% indicated that the existing pricing system discourages them from
performing generic drug substitution. Most respondents indicated that physicians are overusing the “non-substitutable”
option (84%) and that there are technical problems with processing the new prescription form (78%). Less than half (47%)
reported that the MOPH is performing regular audits on the forms collected by the pharmacy. While 45% of the
respondents indicated that consumers have accepted most of the generic substitutions, 21% perceived the increase in
generic drug dispensing to be significant. Findings suggested a potentially significant association between being informed
about generic drugs and respondents’ support of the policy. Suggested strategies to address implementation challenges
included strengthening stewardship function of MOPH, securing full commitment of health care providers, conducting
educational and awareness campaigns about generic drugs and generic drug substitution, and aligning incentive systems
of the key stakeholders.
Conclusions: The majority of community pharmacists were supportive of generic drug substitution in general but not of
the current implementation of the policy in Lebanon. Findings revealed implementation challenges at the provider, patient,
and system level which are hindering attainment of the policy objectives. The key lessons derived from this study can be
used for continuous improvement of the policy and its implementation.
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Background
Ensuring access to medicines with assured quality,
safety, and efficacy is considered a main component
towards improved health outcomes [1]. According to
estimates from the World Health Organization (WHO),
the percentage of population without adequate access to
essential medicines is less than 1% in high-income coun-
tries, 24% in middle-income countries, and 39% in low-
income countries. This percentage rises to 50% in the
poorest countries of Asia and Africa [2, 3].
One of the main barriers to access to medicine is their
high costs [4, 5]. Generic medicines provide opportun-
ities for major savings in healthcare expenditure due to
their low price [6, 7]. Generic medicines are bioequiva-
lent to their branded counterparts but are generally 20–
90% less expensive [8–10]. The underuse of generics is
considered as one of the leading causes of economic in-
efficiency in healthcare [11]. It has been estimated that
switching procurement from branded drugs to the
lowest-priced generic equivalents in the private sector in
17 developing countries could result in an average of
60% cost savings [12].
Governments in both developed and developing coun-
tries have introduced generic drug substitution (GS) pol-
icies to decrease pharmaceutical expenditures and
improve access to medicine [6, 13]. Generic substitution
allows pharmacists to dispense a generic drug containing
the same active ingredient, form, dosage, and strength as
the originator drug prescribed by the physician [14]. The
laws governing generic substitutions vary from mandat-
ing pharmacists to substitute brand drugs with thera-
peutic equivalent generics unless prohibited by the
prescriber (i.e., mandatory GS), to allowing pharmacists
to perform generic substitution (i.e., permissive GS) and
requiring patients’ consent before generic substitution
[13]. Generic substitution is mandatory in six European
countries (Sweden, Germany, Norway, France, Finland,
and Spain) and permissive in others (Portugal, Denmark,
Italy, Poland, Czech Republic, The Netherlands,
Hungary, Poland, and Latvia) [15]. In the USA, generic
substitution is a common practice with pharmacists sub-
stituting up to 84% of brand drug prescriptions for
which generic equivalents are available [13].
The Lebanese context
Pharmaceuticals account for over 25% of the total
healthcare expenditure in Lebanon [16, 17] compared to
an average of 17% in countries of the Organization for
Economic Co-operation and Development (OECD) [18].
Lebanon’s per capita pharmaceutical spending is consid-
ered one of the highest in the Middle East [19]. In 2009,
it was estimated that over 25% of household annual ex-
penditures was spent on medications [17].
The pharmaceutical sector in Lebanon is dominated
by imported medicines and patented brand names which
constitute more than 80% of the total market share [17].
Around 40% of the Lebanese population have no form
of health insurance coverage while the remaining 60%
are insured either through public or private insurance.
However, only around 20% of drugs consumed are
thought to be reimbursed through one of the schemes
[19].
Generic drug substitution has been proposed as a pol-
icy instrument in Lebanon to promote generic drug use
and alleviate the extremely high cost of pharmaceuticals
on households, government, and insurers. In March
2010, Parliament approved a law that provided pharma-
cists the right of substitution between a brand-name
drug and a matching generic one under certain condi-
tions (see Table 1). In 2011, the MOPH issued




The policy stipulated that pharmacists may disburse to bearers of prescription drugs generic medicines not mentioned in
the prescription under the following conditions:
•Alternative medicine should be included in the list of alternative medicines published by the MOPH in accordance with
the WHO standards.
•The medicine should contain the same active ingredient as the one mentioned in the prescription and in the same
quantities and pharmacological form.
•The price of sale of the substituted medicine in Lebanon should be less than the price of sale of the prescribed medicine.
•The patient must agree to the substitution.
•The physician must indicate acceptance of substitution. The pharmacist cannot change the prescription if the physician
ticked the “Non-substitutable” (NS) box.
Unified medical
prescription form
The old prescription form has been replaced with a new unified medical prescription form that permits generic drug
substitution:
•Patients, pharmacists, and health care providers are required to use one combined (i.e., unified) medical prescription form.
•The form should be distributed in three copies: one for the physician, one for the patient, and one for the pharmacist.
•The form is composed of several sections targeting physicians, pharmacists/radiologists/laboratory staff, insured patients,
and insurance parties.
•There is an option, in the form, that allows the physician to prescribe non-substitutable medications as per the 47th
article of the practice law of pharmacy profession.
•Physicians are required to purchase the form from the Order of Physician.
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ministerial decision no. 1295, publishing the sample uni-
fied medical prescription form in three copies (one for
the doctor, one for the pharmacist, and one for the
patient) (see Table 1). However, the law was not officially
implemented up until August 2015. The 4-year gap
between its issuance and its implementation was a result
of administrative hurdles and impediments from various
stakeholders with commercial interests [20].
Assessing the implementation of a policy early on is
critical as country experiences have shown that once
policies are adopted, they are not always implemented as
planned and do not necessarily achieve intended out-
comes [21]. We are not aware of any study that has
assessed the perception and reported practices of phar-
macists with regards to implementation of the new gen-
eric drug substitution policy in Lebanon. A focus on
pharmacists is critical given their strong influence on pa-
tients’ decisions and their pivotal role in the success of
generic drug substitution policy [22–24]. Therefore, the
objective of this exploratory study was to examine the
attitudes of community pharmacists and the reported
practices in relation to the implementation of the new
generic drug substitution policy in Lebanon. It also
aimed to gain a better understanding of emerging chal-
lenges as well as strategies that can be adopted to im-
prove implementation of the policy.
Method
Study design and population
The study utilized a convergent mixed methods ap-
proach composed of both quantitative and qualitative
components [25, 26]. Data collection was concurrent
whereby respondents were first asked to complete a
questionnaire followed by a semi-structured interview
based upon their consent. The purpose of using a mixed
methods approach was to expand on the ideas presented
in the questionnaire to yield a more comprehensive un-
derstanding of the issue [27].
The study population consisted of licensed pharma-
cists and pharmacy technicians who work as frontline
staff in community pharmacies in Lebanon. The sam-
pling unit was community pharmacy, and the sampling
frame was the list of 2806 licensed community pharma-
cies obtained from the Order of Pharmacists’ website.
For the quantitative component, the sample size was
calculated based on 90% CI, a margin of error of 5%,
and the assumption of 80% adherence rate to the rules
that govern the unified medical prescription. This gener-
ated a sample size of 164 using an online sample size
calculator [28]. A stratified convenience sampling
method based on the six governorates (Beirut, Mount
Lebanon, North Lebanon, Bekaa, South Lebanon, and
Nabatiye) was used to select the pharmacies. To achieve
this, we first stratified the pharmacies by governorate.
We then selected a convenient sample of around 30
pharmacies from each governorate.
For the qualitative component, we invited respondents
who completed the questionnaire to participate in semi-
structured interviews. We opted to interview at least 5–
6 pharmacists from each governorate.
Survey instrument
The initial questionnaire was developed by the research
team after an extensive review of the literature on gen-
eric drug substitution [24, 29–31]. Some of the items
were adapted from existing measures whereas others,
specifically those pertaining to the broader health system
(e.g., receptiveness of MOPH), were created by the
research team. The questionnaire was structured in line
with the study objectives, taking into consideration the
multitude of factors that may affect implementation of
the new policy. We asked one community pharmacist,
one professor of pharmacy, and one professor of
pharmacology to review the questionnaire for face and
content validity. We then pilot-tested the questionnaire
with three community pharmacists (not involved in the
actual study) and refined it based on their inputs. We
originally developed the questionnaire in English and
then translated it into Arabic language (which is the
local language in Lebanon) by a professional translator.
The questionnaire was back-translated by an independ-
ent researcher and any discrepancies were resolved
through discussions with the core team. Both the Eng-
lish and Arabic versions were available, depending on
participants’ preferences (see Additional file 1).
The final questionnaire consisted of the following five
sections:
– Demographic and professional characteristics. These
were measured by seven closed-ended questions and
one open-ended question.
– Respondents’ attitudes towards generic drug
substitution and the unified medical prescription.
These were measured by three scales (each
composed of several items): Attitude towards
Generic Drug Substitution (two items), Attitude
towards the Unified Medical Prescription (four
items), and Layout/Structure of Form (two items).
Each item was rated on a range from 1 to 5 where 1
indicates “Strongly disagree” and 5 indicates
“Strongly agree.” Similar response scale and anchors
were used elsewhere [32].
– Reported practices in relation to the implementation
of the new generic drug substitution policy. These
were measured by six scales (each composed of
several items): Pharmacist Practices (five items);
MOPH Responsiveness (four items); Functionality of
Form (five items), Consumer Acceptance (four
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items); Outcome of Policy (five items); and Relation
with Drug Companies (two items). Each item was
rated on a range from 1 to 5 where 1 indicates
“Strongly disagree” and 5 indicates “Strongly agree.”
– Perceived barriers to the implementation of the
generic drug substitution policy. This was measured
by one open-ended question.
– Suggested strategies to improve the implementation
of the generic drug substitution policy. This was
measured by one open-ended question.
The semi-structured interviews complemented and ex-
panded on the questionnaire data by exploring participants’
experiences with implementing the new policy including
perceived barriers and facilitators. The interviews were
guided by an interview guide developed by the research
team (see Additional file 1).
Data collection
The study was approved by the Institutional Review Board
at the American University of Beirut. Data was collected
between January 2016 and March 2016. We randomly
approached one pharmacy personnel from each selected
community pharmacy. Whenever a selected pharmacy did
not have a licensed pharmacist working as frontline staff,
we sampled the pharmacy technician instead. Respon-
dents were informed of the objective of the study and a
verbal consent form was provided. Upon approval of
respondents, a member of the research team provided the
survey for self-completion; respondents were not asked to
provide their names or that of their pharmacy to maintain
confidentiality of responses. After survey completion,
respondents were asked whether they were interested in
taking part in the qualitative part.
The semi-structured interviews were conducted in the
selected pharmacies by a member of the research team
and lasted between 10 and 15 min each. The interviews
were not audio-recorded; instead, thorough notes were
taken by the interviewer. Interviews were conducted in
Arabic and subsequently transcribed verbatim. All tran-
scripts were translated to English by two members of
the research team (RF and NH) and results were cross-
validated.
Data analysis
Data generated from the survey was entered and ana-
lyzed using statistical package SPSS 23.0 (p value = 0.05).
To account for limited responses per category and facili-
tate interpretation, we grouped the responses for
“Strongly agree” and “Agree” under the heading
”Strongly agree/Agree” and the responses for “Strongly
disagree” and “Disagree” under the heading “Strongly
disagree/Disagree”. The “Neutral” heading was retained.
The percentage of positive responses for each item was
calculated; negatively worded items were reversed when
computing percent positive response (see Additional file
2 for results of the full Likert scale).
Scale scores were computed by summation of the
item-based scores within the scale and dividing by the
number of items with non-missing values. This gener-
ated a score that ranged from 1 to 5 for each scale, with
higher scores signifying higher agreement to the item
being assessed.
We used Cronbach’s alpha to measure the internal
consistency and reliability of the scales. While Cron-
bach’s alpha values of 0.7 and above are recommended, a
value of 0.6 or even lower can still be acceptable espe-
cially in exploratory studies and social sciences research
[33, 34]. Bowling (1997) states that a value of 0.5 or
above indicates good internal consistency [35], with
lower values expected when using psychological con-
structs due to diversity of constructs being measured
[36]. For the purpose of this exploratory study, items
were considered to represent acceptable level of internal
consistency if the Cronbach’s alpha value was 0.5 or
above. Where applicable, we used the “alpha if item
deleted” function to improve the internal consistency of
scales while also ensuring there is no loss in criterion
validity [37].
We used T tests to examine the association between
the scales and the following variables: gender, profession,
post-graduate qualification, ownership status of phar-
macy, and whether or not the pharmacists received any
teaching about generic versus brand-name drugs. We
used ANOVA test to assess the association between the
scales and the following variables: age, governorate, and
country of education.
For the qualitative component, we conducted thematic
analysis of the data generated from the interviews and the
open-ended questions. We first coded the responses using
an Excel spreadsheet. Then, two members of the research
team (RF and NH) independently conducted open coding
to segregate the findings into chunks that relate to similar
concepts. This was followed by axial coding to organize
emerging concepts into themes and subthemes that reflect
study objectives and survey scales [38, 39]. They cross-
checked and verified the identified themes.
Results
Quantitative results
Demographics and professional characteristics
Out of a total of 204 sampled pharmacies, 153 pharmacies
had one individual agree to participate (75% response
rate). The response rate by governorate is provided in
Additional file 3. The majority of participants were
licensed pharmacists (84.9%), between 20–40 years of age
(69.6%), and have obtained their degrees from Lebanon
(71.6%). Slightly, over half were males (51.4%) and owners
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of the pharmacy (56.2%). Around 75% reported receiving
teachings about generic versus brand-name drugs. Only
38.7% of participants reported holding a postgraduate
qualification (PharmD). Participants were roughly distrib-
uted across all six governorates, with Beirut (the capital
city of Lebanon) having the highest number of partici-
pants. Table 2 shows the demographic and professional
characteristics of respondents.
Scale-based components
The Cronbach’s alpha value was above the cutoff value
of 0.5 for all but three scales, indicating acceptable level
of internal consistency. However, the value for each of
the scales “Functionality of Form”, “Consumer Accept-
ance”, and “MOPH Responsiveness” was below 0.5, indi-
cating poor level of internal consistency (see Table 3).
The mean scores computed for the different scales
varied between 2.47 and 3.78 (on a range from 1 to 5).
“Attitudes towards Generic Drug Substitution” had the
highest mean score (3.78), indicating higher average
agreement to the items being assessed whereas “Func-
tionality of Form” (2.47) had the lowest score, reflecting
poor average agreement to the items being assessed (see
Table 3). The details of each scale and corresponding
items are further discussed below. We grouped the
scales into those assessing respondents’ attitudes and
those assessing reported practices, respectively.
Respondents’ attitudes towards generic substitution and the
unified medical prescription
Respondents’ attitudes were assessed using the following
three scales: “Attitude towards Generic Drug Substitu-
tion”, “Attitude towards the Unified Medical Prescrip-
tion”, and “Layout of Form”.
Respondents expressed positive attitude towards generic
drug substitution in general, with 64% supporting generic
drug substitution for all brand-name drugs for which ge-
nerics are available. In addition, it was acceptable for 81%
of respondents that pharmacists perform generic substitu-
tion without obtaining permission from the prescribing
physician. On the contrary, respondents expressed less
positive attitudes towards the unified medical prescription,
with only 37% supporting its current implementation in
Lebanon. Furthermore, less than half of respondents
agreed with the statements that it promotes the use of
generic drugs in Lebanon (44%) or that it helps regulate
the pharmaceutical industry (32%). Respondents who indi-
cated receiving teachings about generic versus brand-
name drugs had significantly higher mean scores regard-
ing attitudes towards the unified medical prescription (p
= 0.035) (see Additional file 4). With regards to the layout
of the form, 55% of the respondents agreed that the form
is user-friendly and 36% indicated that that they are satis-
fied with its overall layout.
Reported practices in relation to the New Generic Drug
Substitution Policy
Reported practices were assessed using six scales:
“Pharmacist Practice”, “MOPH responsiveness”, “Func-
tionality of Form”, “Consumer Acceptance”, “Relations
with Pharmaceutical Industry”, and “Outcome of Policy”.






Mount Lebanon 23 15
North Lebanon 29 19
Nabatiye 21 14





20–30 years 64 42
31–40 years 41 27
41–50 years 34 23
51–60 years 8 5
60+ years 4 3
Professional status
Pharmacist 129 85




Country where degree was obtained
Lebanon 106 72
Eastern Europe 20 14
Other (Libya, Russia, Syria, and Venezuela) 12 8
Western Europe 8 5
North America 2 1
Years of experience
Less than 10 years 84 63




Teaching about generic versus brand-name drugs
Yes 109 74
No 38 26
aAll percentages have been rounded to one decimal point
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Table 3 Descriptive statistics and Cronbach’s Alpha on survey scales










Attitude towards generic drug substitution (Cronbach’s alpha = 0.553) 3.78 0.85 49 (16) 35 (12) 219 (72)
1.I support generic substitution for all brand-name drugs for which
generics are available.
3.55 1.01 30 (20) 25 (16) 97 (64)
2.It is acceptable that pharmacists perform generic substitution without
obtaining permission from the prescribing physician.
4.01 1.03 19 (12) 10 (7) 122 (81)
Attitude towards unified medical prescription (Cronbach’s alpha = 0.529) 3.16 0.77 200 (33) 122 (20) 277 (46)
1.I support the implementation of the unified medical prescription. 2.94 1.22 58 (39) 36 (24) 55 (37)
2.The unified medical prescription helps promote the use of generic
drugs in Lebanon.
3.09 1.25 53 (35) 31 (21) 66 (44)
3.The unified medical prescription helps identify physicians who are
influenced by medical representatives.
3.89 1.09 20 (13) 22 (15) 107 (72)
4.The unified medical prescription helps regulate the pharmaceutical
industry.
2.83 1.2 69 (46) 33 (22) 49 (32)
Layout/structure of form (Cronbach’s alpha = 0.705) 3.16 0.77 88 (29) 78 (26) 138 (45)
1.I am satisfied with the overall layout of the form. 2.89 1.09 57 (38) 40 (26) 55 (36)
2.The form is user-friendly. 3.32 1.01 31 (20) 38 (25) 83 (55)
Pharmacist practices (Cronbach’s alpha = 0.566) 3.30 0.64 186 (25) 193 (26) 376 (50)
1.Pharmacists are adhering to the laws that govern the unified medical
prescription.
2.11 1.18 29 (19) 33 (22) 90 (59)
2.I have substituted brand drugs for generic equivalents in most of the
prescriptions I have dispensed (excluding those prescriptions where the
NS option was ticked).
3.04 1.14 53 (35) 38 (25) 60 (40)
3.I feel empowered to speak to patients about generic drug substitution
since the implementation of the policy.
2.99 1.01 50 (33) 51 (34) 50 (33)
4.I sometimes consult with the physician when I feel the NS option is
used unjustifiably.
3.32 1.18 42 (28) 27 (18) 82 (54)
5.I have been adhering to the Ministry of Public Health’s (MOPH) agreed
list of substitutable generic drugs.
3.65 0.85 12 (8) 44 (29) 94 (63)
MOPH responsiveness (Cronbach’s alpha = 0.324) 117 (29) 173 (29) 311 (42)
1.The MOPH performs regular audits on the prescription forms collected
by the pharmacy.
3.21 1.13 36 (24) 43 (29) 71 (47)
2.Generic drug equivalents approved by the MOPH are almost always
in stock.
3.56 0.81 16 (11) 42 (28) 92 (61)
3.The MOPH’s national list of substitutable generic drugs is updated,
accessible and easy to use.
3.18 1 38 (25) 51 (34) 63 (41)
4.The existing price structure discourages me from performing generic
drug substitution.b
2.51 1.01 27 (18) 37 (25) 85 (57)
Functionality of form (Cronbach’s alpha = 0.452) 180 (75) 88 (12) 486 (13)
1.Physicians are adhering to the laws that govern the unified medical
prescription form.
2.11 1.18 108 (72) 19 (13) 23 (15)
2.There are technical problems with the implementation of the unified
medical prescription form.b
2.14 0.9 17 (11) 16 (11) 119 (78)
3.There are no clear guidelines on how to use the forms.b 2.36 1.06 27 (18) 21 (14) 104 (68)
4.Physicians in general are abusing the NS option.b 1.83 0.99 12 (8) 12 (8) 127 (84)
5.Some patients still show up with the old prescription form.b 2.03 1.08 16 (11) 20 (13) 113 (76)
Consumer acceptance (Cronbach’s alpha = 0.472) 168 (50) 130 (22) 305 (28)
1.Consumers generally express negative attitudes towards generic drugs.b 2.61 1.13 39 (26) 28 (19) 83 (55)
2.Consumers are not generally happy with the unified medical prescription.b 2.2 0.89 13 (9) 34 (22) 105 (69)
2.89 1.06 62 (41) 39 (26) 50 (33)
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When it comes to pharmacists’ practices, over half of
the respondents indicated that pharmacists are adhering
to the laws that govern the unified medical prescription
(59%). Similarly, 63% agreed that they are adhering to
the MOPH’s list of substitutable generic drugs. Nonethe-
less, only 40% reported that they have substituted brand
drugs for generic equivalents in most of the prescrip-
tions they have dispensed for which substitution was
allowed. Furthermore, 33% agreed that they felt more
empowered to speak to patients about generic drug sub-
stitution since implementation of the policy (see Table 3).
Respondents who indicated receiving teachings about
generic versus brand-name drugs had significantly
higher mean scores regarding pharmacist practices (p <
0.001). On the contrary, significantly lower mean scores
were observed among respondents reporting less than
10 years of experiences (p = 0.049) (see Additional file 4).
With regards to their relations with pharmaceutical
companies, 24% of respondents agreed with the state-
ment that their drug substitution choice is influenced by
information from medical drug representatives.
When asked about MOPH responsiveness to the new
policy, 47% of the respondents indicated that the MOPH
is performing regular audits on the unified medical
prescription forms. In addition, 41% agreed that the
national list of substitutable generic drugs is updated,
accessible, and easy to use. Furthermore, 57% indicated
that the existing pricing system set by the MOPH
discourages them from performing generic drug substi-
tution. Those who reported having less than 10 years of
experience had significantly lower mean scores regarding
MOPH responsiveness to the policy (p = 0.009).
With regards to functionality of the unified medical
prescription form, the majority of respondents agreed
with the statements that physicians are overusing the
“non-substitutable” option (84%) and that they are not
adhering to the laws that govern the unified medical pre-
scription (72%). Most respondents also indicated that
there are technical problems related to processing the
forms (78%), with no clear guidelines on how to use
them (68%). Furthermore, 76% indicated that consumers
still show up to the pharmacy with the old prescription
form. As for consumer acceptance, the majority of re-
spondents agreed with the statements that consumers
have expressed negative attitudes towards generic drugs
(55%) and the unified medical prescription (69%). In
addition, 45% reported that consumers have accepted
most of the generic drug substitutions, and one-third
indicated that consumers have actively requested generic
substitution for brand-name drugs.
The questionnaire also attempted to assess the outcome
of the new policy. Less than a quarter of respondents
(21%) indicated that the number of generic dispensing at
their pharmacies has increased considerably after imple-
mentation of the policy. In addition, around one-third
(34%) indicated that the overall patient expenditure on
medicine has decreased after its implementation. Further-
more, 30% agreed that there has been a noticeable shift in
pharmaceutical companies’ promotional strategies target-
ing pharmacists after implementation of the policy.
Table 3 Descriptive statistics and Cronbach’s Alpha on survey scales (Continued)
3.Consumers have been actively requesting generic substitutions for
brand-name drugs.
4.Consumers have accepted most of the substitution suggestions offered
by the pharmacy.
3.1 1.06 54 (36) 29 (19) 67 (45)
Relation with drug companies (Cronbach’s alpha = 0.629) 2.76 0.92 140 (47) 68 (23) 92 (31)
1.My drug substitution choice is influenced by information from medical
drug representatives.
2.6 1.01 79 (52) 36 (24) 36 (24)
2.It is acceptable that pharmacists rely on medical drug representatives
to learn about alternative drug substitutions.
2.91 1.15 61 (41) 32 (21) 56 (38)
Outcome of the policy (Cronbach’s alpha = 0.511) 2.67 0.61 299 (50) 188 (25) 271 (25)
1.The number of generic dispensing at my pharmacy has increased
considerably since the implementation of the policy.
2.59 0.97 81 (53) 39 (26) 32 (21)
2.There was an initial peak in generic dispensing following the
implementation of the policy that was subsequently attenuated.
2.72 1.02 73 (48) 39 (26) 40 (26)
3.The overall patient expenditure on medicine has decreased since the
implementation of the policy.
2.86 1.09 69 (45) 31 (20) 52 (34)
4.There has been a noticeable shift in pharmaceutical companies’
promotional strategies targeting pharmacists.
2.97 1.05 53 (35) 53 (35) 46 (30)
5.The policy is creating conflicts between the physician, the pharmacist,
and the patient.b
3.77 1.09 23 (15) 26 (17) 101 (67)
aAll percentages have been rounded to the nearest one
bReverse scores
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Ownership of pharmacy, age, professional status, and
country of degree were not found to be significantly
associated with any of the scales (see Additional file 4).
Qualitative results
Seventy-five and 55 individuals, respectively, completed
the first and second open-ended question. In addition,
29 individuals from all but one governorate (Nabatiye)
participated in the semi-structured interviews. The
emerging themes were grouped under the following two
main domains: barriers to implementation of the generic
drug substitution policy and strategies to facilitate its
implementation, respectively. Additional file 5 summa-
rizes the emerging themes in tabular format, categorized
into patient, provider, organizational, and systems level.
Perceived barriers to implementation of the policy
An overarching barrier was the lack of preparedness of
end users to implement generic drug substitution policy,
with subsequent poor adherence and lack of clarity on
the purpose, rights, and expectations from each party.
The overuse of the “non-substitutable (NS)” option for
unjustified reasons was highlighted as a main obstacle
hindering generic drug substitution. This has been exac-
erbated by the absence of mechanisms to monitor the
prescribing patterns of physicians. As stated by one
participant:
“The policy did nothing; doctors found their way
around it by marking ‘NS’ in most prescriptions, even
for those where another equivalent medication exists
with a lower price”—[Interviewee 15; female
pharmacist; Beirut]
Another frequently reported challenge is the lack of
adherence of some physicians to the policy. This is man-
ifested in their continued use of the old prescription
form specifically with patients who are uninsured or
who have private insurance. In addition, some physicians
have been charging patients for the new form as a way
of shifting the cost burden to them, as highlighted by
one participant:
“The price of the form is problematic; some physicians
are charging patients up to 20,000 [Lebanese Pounds]
for the form” (US$1 = 1506.5 Lebanese Pound
(LBP))—[Interviewee 8; male pharmacist; Mount
Lebanon]
Furthermore, participants reported that dispensaries
and governmental hospitals were still using the old
prescription form. This, in turn, has serious implica-
tions as patients coming from these settings are the
most in need of non-expensive drugs and thus could
benefit from the new prescription form which permits
generic substitution.
Physicians’ relationship with the pharmaceutical indus-
try was another perceived factor hampering proper im-
plementation of the generic drug substitution policy.
According to participants, this has prompted some phy-
sicians to persuade patients into refusing generic substi-
tutions offered by pharmacists.
Another recurrent barrier related to insufficient policy
support from pharmacists themselves due to lower prof-
itability, increased administrative burden, resistance
from consumers, and a perceived sense of “disrespect to
the pharmacy profession as a whole, due to the “NS” op-
tion”. In addition, a number of pharmacists stated that
they still accept the old prescription form for the pur-
pose of customer retention, as illustrated below:
“I have been losing customers because some doctors
are writing on a white paper [instead of the new
prescription form] and I’m not accepting it while other
pharmacies are…”—[Interviewee 3; male pharmacist;
North Lebanon]
Participants frequently mentioned that the existing
pricing system also impacts the success of the generic
drug substitution policy according to the following sce-
nario: the pricing strategy adopted by the MOPH prior
to the introduction of the new policy had led to a signifi-
cant reduction in the prices of brand-name drugs. With
the launching of the unified medical prescription, several
pharmaceutical companies were prompted to further
lower the prices of their patented drugs to compete with
generics. Consequently, the prices of some brand drugs
became similar to, and in some cases, lower than those
of their generic equivalents. According to participants,
this scenario undermined the purpose of the policy to
promote generic drugs in the first place. This has been
further exacerbated by the absence of an incentive
system to encourage pharmacists to perform generic
substitutions.
Additional reported barriers included insufficient
awareness and education of providers, patients and
third-party insurers about generic drugs, and the new
drug substitution policy as well as poor trust in the
quality of generics in the market. Some participants
also pointed to administrative hurdles related to
processing of bills by third party payers for drugs
disbursed according to the new prescription form (see
Additional file 5).
Suggested strategies to improve implementation of the policy
Securing the full commitment of physicians was repeat-
edly suggested as crucial for successful implementation
of the generic drug substitution policy. Whereas a
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number of participants supported the complete elimin-
ation of the “NS” option from the form, the majority
preferred the establishment of mechanisms to discour-
age its overuse such as a minimum permissible number
of NS that can be marked by a physician per month for
different classes of drugs. One participant also suggested
computerizing the medical prescription form to
strengthen the implementation process.
A number of participants indicated that the MOPH
should conduct periodic monitoring and inspections,
primarily of physicians and dispensaries, as well as enforce
legal and non-legal measures on entities that violate
implementation of the policy. They also pointed to the
need to ensure the quality of generic drugs circulating the
market, including strengthening the registration proced-
ure and mandating quality and bioequivalence testing of
drugs entering the market. Some participants also
highlighted the need for educational and awareness cam-
paigns about generic drugs in general and the unified
medical prescription in particular. They also stressed on
the importance of establishing incentive systems to en-
courage generic drug substitution.
Participants also pointed to the need to reduce admin-
istrative burdens associated with processing the form
due to inconveniences and delays in treatment associ-
ated with sending a patient or even a family member
back to the physician to correct or complete the
prescription form. Additional highlighted strategies
included: subsidizing or providing free consultation visits
to poor patients so that they can afford such visits when-
ever they need a medication (particularly for refill
prescriptions), establishing appropriate pricing policies
that create a competitive market for generic drugs, and
regulating interactions between healthcare providers and
drug companies (see Additional file 5).
Discussion
Summary and interpretation of findings
The findings from this study revealed that the majority
of pharmacists supported generic drug substitution in
general. In spite of this favorable attitude, respondents
were not fully supportive of the current implementation
of the policy in Lebanon. While the main aim of this
policy instrument was to reduce medicine expenditures
by promoting generic drugs, findings revealed that phar-
macists did not perceive the increase in generic drug
dispensing or the decrease in overall patient expendi-
tures to be significant. That being said, pharmacists
believed that the policy had an important influence on
the pricing strategies of some pharmaceutical companies
by pressuring them to lower the prices of their brand-
name drugs to compete with generic equivalents. On the
one hand, this makes competition policy a potentially
important policy option in LMICs [6]; on the other
hand, and as reported by respondents, it may also
discourage generic substitution for those drugs whose
prices have become similar to their generic equivalents.
This, in turn, highlights the importance of establishing
appropriate medicine prices and pricing systems to pro-
mote generic drugs [40].
The findings also pointed to poor adherence of the key
stakeholders including physicians, pharmacists, and
patients to the policy. The majority of respondents indi-
cated that physicians and dispensaries have not been
adhering to the new form with continued use of the old
form, especially among patients who are uninsured or
who have private insurance. This has financial and
health implications given that almost half the population
in Lebanon lacks insurance coverage [17]. Where the
new prescription form is being utilized, a significant
number of physicians seem to be overusing the NS op-
tion. One reason for this could relate to unethical pro-
motional incentives by pharmaceutical industries.
Furthermore, some physicians are reportedly charging
patients for the form, which represents an additional
burden for them. As for pharmacists themselves, they
have admitted to accepting the old form due to fear of
losing customers to other pharmacies. Furthermore, they
have refrained from performing generic substitution for
many prescriptions that allowed substitution; a fre-
quently reported reason related to the poor incentive
system in place to encourage generic substitution. With
regards to consumers, they have reportedly demon-
strated poor acceptance of generic drugs and generic
drug substitution, possibly due to poor knowledge of
generic drug substitution, and a preference for drugs
prescribed by physicians. Findings suggested a poten-
tially significant association between being informed
about generic drugs and respondents’ support of the
generic substitution policy.
Perspectives in the literature on the key components
of successful policy implementation have been summa-
rized in a framework encompassing seven dimensions:
the policy, its formulation, and dissemination; social,
political, and economic context; leadership for policy
implementation; stakeholder involvement in policy im-
plementation; implementation planning and resource
mobilization; operations and services; and feedback on
progress and results [23]. By matching the challenges
reported in our study to this framework, it becomes
evident that the policy implementation in Lebanon has
been challenged by insufficient dissemination and under-
standing of the policy by those responsible for and
affected by its implementation; insufficient attention to
the socio-economic factors outside the policy process;
lack of strong leadership to ensure follow-through,
resources, and accountability for translating the policy
into practice; poor coordination mechanisms and
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commitments of individuals and organizations respon-
sible for delivering the services outlined in the policy;
and weak capacity of the MOPH to regularly monitor,
collect, disseminate, and use feedback to evaluate pro-
gress towards attainment of the policy goals.
Comparison to findings from other studies
Similar to this study, findings from studies conducted in
Malaysia, New Zealand, Czechia, and Saudi Arabia
found that pharmacists support generic drug substitu-
tion in general [23, 30, 32, 41]. However, contrary to our
finding, the majority of pharmacists in Iran (71.6%) and
the USA (83.8%) stated that they have generically
substituted prescriptions that allowed generic substitu-
tion [42, 43]. While this may reflect obstacles in imple-
mentation of the policy in Lebanon, it is also important
to take into consideration that the policy is still in its
first year of implementation.
Contrary to our findings, a study conducted in
Australia found that less than 20% of prescriptions dis-
pensed had substitution prohibited by the physician [44].
Although the NS option may be used for drugs with nar-
row therapeutic indices [43, 45], it is estimated that the
maximum prescription rate that can be filled by generic
drugs can reach up to 80% [46].
Challenges reported in this study paralleled those
reported in other studies. These included poor adher-
ence of physicians and pharmacists to the new policy
[45], lack of trust of health professionals and consumers
in quality and bioequivalence of drugs [47–49], incen-
tives from pharmaceutical companies [50], and absence
of appropriate medicine prices and pricing systems to
promote generic medicine [45, 48]. Findings on the key
enablers for promoting generic drug substitution con-
firmed those reported previously and included the pres-
ence of supportive legislation and regulations to promote
a competitive market for generic drugs, creation of a
trusted medicines regulatory authority, quality assurance
capacity, acceptance by health professional and the public,
and pro-generic drug incentives for prescribers, dispensers
and patients [6, 13, 32, 43].
Strengths and limitations
To our knowledge, this is the first study to assess the
implementation of the generic drug substitution policy
in Lebanon. The study is timely as it constitutes a base-
line assessment of the policy following its early imple-
mentation. In addition, data triangulation through the
use of surveys and semi-structured interviews strength-
ened the internal validity of our findings. Furthermore,
the survey achieved an overall response rate of 75%,
which is considered acceptable.
The study has a number of limitations that should be
taken into consideration when interpreting the results.
First, the findings on current practices are based on the
perception of pharmacists, and not on objective data,
such as prescription records at pharmacies. However, as
prescription records are not readily available or access-
ible in Lebanon, we employed data triangulation to help
validate the findings. Another limitation relates to the
questionnaire where the Cronbach alpha’s score was
below 0.5 for three scales. Since discarding some of the
items using the “alpha if item deleted” function did not
significantly alter the Cronbach’s alpha coefficients, it is
possible to attribute the low internal consistencies for
these constructs to the small number of items (fewer
than 10) included in the scales [51]. Future surveys
should consider revising some of the survey questions to
enhance scale reliability. A further limitation is the
cross-sectional study design which reflects only one
point in time and therefore may not capture changes in
respondents’ attitudes and practices over time. While
these studies cannot ascertain a causality relationship for
any observed association, they can still provide useful
information on magnitudes, patterns, and trends which
can help inform proper implementation. Finally, it is
important to note that we could not evaluate the repre-
sentativeness of the respondent demographics due to the
absence of a national data on characteristics of commu-
nity pharmacists. However, we believe that this sample is
likely to be representative. First, we sampled pharmacists
from all six provinces in Lebanon, which enhanced the
geographical representativeness of the findings. Second,
a study of the pharmacy manpower in Lebanon found
that newly graduated (and young) pharmacists were
more likely to work in community pharmacists [52];
thus, we can deduce that a response bias was unlikely to
have occurred.
Implication for policy and practice
As a lead entity in Lebanon, the MOPH should play a key
role in coordination and oversight of the generic drug sub-
stitution policy, monitor the extent of implementation and
achievement of targets, and establish consequences for
non-compliance. These should be complemented by sup-
porting policies to ensure appropriate pricing and purchas-
ing strategies as well as regulate interactions of health care
provider with pharmaceutical industries. Additional efforts
should be invested in publicizing the national substitution
drug list as well as issuing a full list of over-the-counter
drugs that can be disbursed by pharmacists without a pre-
scription form. Professional associations should also play a
leading role in ensuring their respective health care profes-
sionals are educated about the purpose of the policy and
are committed to its proper implementation.
The establishment and alignment of stakeholder incen-
tives is another critical area worth considering. The MOPH
could consider establishing quality and accreditation
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standards for pharmacies and ensure generic substitution
goals and indicators are integrated as part of the remuner-
ation system for pharmacists [53, 54]. As for physicians,
prescribing targets for generic drugs could be established
and linked to financial incentives and performance ap-
praisals [48, 54]. Considerations could also be given to es-
tablish limits on the number of times the NS option can be
marked by a physician per month for certain drug classes.
Professional acceptance of the policy can further be facili-
tated by utilizing generic names in clinical guidelines and
formularies and providing a cross-reference list of brand
and generic names for all prescribers [55]. As for patients,
subsidizing consultation visits, particularly for the poor and
those with refill prescriptions, could be considered.
Another important area relates to strengthening
pharmaceutical regulations to ensure quality and avail-
ability of generic medicines [56]. This could be comple-
mented by media campaigns to raise awareness and
educate health care professionals and the general public
about generic drugs and demystify misconceptions about
inferiority of generics relative to branded drugs [14].
Equally important is the need to incorporate courses on
generic drugs in the undergraduate curricula of pharma-
cists to help support generic substitution and implemen-
tation of the new policy [57, 58].
Finally, to ensure sustainability, it is critical to establish
measurable indicators for ongoing monitoring and
evaluation at all stages of policy implementation [40].
Computerization of the unified medical prescription
form at later stages can facilitate ongoing and timely
surveillance as well as alleviate reported administrative
hurdles related to processing the form.
Implications for research
It is important to follow up on the policy implementa-
tion in the upcoming years, using more robust studies.
These would assess more objective outcomes (e.g., actual
as opposed to reported practices) and use better meth-
odological designs such as interrupted time series or
pre–post studies. Additional research is needed on the
practices of hospital pharmacists given the different
regulatory measures employed in such context. Future
research could also explore physicians’ and consumers’
perceptions and practices in relation to the implementa-
tion of the generic drug substitution policy.
Conclusions
The majority of community pharmacists were supportive
of generic drug substitution in general but not of the
current implementation of the policy in Lebanon. Al-
though the policy may be well intentioned at its core, the
realization of its objectives has been undermined by weak-
nesses in implementation of the unified medical prescrip-
tion form and absence of supporting policies and
incentive systems to minimize perverse behaviors. Secur-
ing the full commitment of pharmacists and physicians,
strengthening the stewardship function of the MOPH, and
establishing pro-generic drug incentives are crucial for
successful implementation of the policy. The key lessons
derived from this study can be used for continuous
improvement of the policy and its implementation.
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